Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anlotinib + bemozulimab + nab-paclitaxel + cisplatin
- Development stage
- Unknown
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This four-drug combination regimen is being investigated as a first-line treatment for advanced biliary tract cancer (BTC). It consists of **anlotinib**, a multitarget tyrosine kinase inhibitor (TKI) that inhibits angiogenesis by targeting VEGFR1-3, FGFR1-4, and PDGFRα/β; **bemozulimab** (TQB2450), a humanized monoclonal antibody targeting the PD-L1 immune checkpoint; and the chemotherapy agents **nab-paclitaxel** (albumin-bound paclitaxel) and **cisplatin**. The rationale for this combination is to leverage the synergistic effects of anti-angiogenic therapy, immune checkpoint blockade, and cytotoxic chemotherapy to overcome the limited efficacy of standard treatments in advanced BTC. A Phase 2 clinical trial (NCT05812430) is currently evaluating the safety and efficacy of this regimen in patients with intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gallbladder cancer.
- Other names
- anlotinib + TQB2450 + nab-paclitaxel + cisplatinAnlotinib and TQB2450 with Chemotherapy
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)FGFR (FGFR family)PDGFRA (Platelet-derived growth factor receptor alpha)KIT (c-KIT proto-oncogene receptor tyrosine kinase)DNAVEGFR3 (Vascular endothelial growth factor receptor 3)TUBB (Tubulin (alpha and beta subunits))VEGFR2 (Vascular endothelial growth factor receptor 2)RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on anlotinib + bemozulimab + nab-paclitaxel + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anlotinib + bemozulimab + nab-paclitaxel + cisplatin.